Compared to PD‐L1 expression profiling and genomic biomarkers—which are important but often restricted to specific tumor subtypes or hereditary cancer forms—our approach provides a broadly applicable, morphology‐based prognostic tool. This evidence concerns the gene CD274 and neoplasm.